JAMA Oncology shared a recent article by Jonas Saal on X:
“A modified classification of progressive disease based on PD patterns in patients treated with immune checkpoint inhibitors showed an association with postprogression survival (PPOS) across various solid tumor.”
Title: Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
Authors: Jonas Saal, Markus Eckstein, Manuel Ritter, Peter Brossart, Julian Luetkens, Jörg Ellinger, Viktor Grünwald, Michael Hölzel and Niklas Klümper
Jarushka Naidoo, Thoracic Oncologist at the Beaumont Hospital Dublin (Ireland), shared a post on X:
“Can patterns of progression on IO, inform future decisions?
-1377patients from 5 phase 3 trials used to create 3 PD risk levels.
– low (existing lesions), intermediate (new lesions), high (both).
– risk score associated with post-PD OS across tumors.
Prognostic, so far.”
More posts featuring JAMA Oncology.